Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 350.40
+9.30 (2.73%)
Aug 14, 2025, 4:59 PM CET
Zealand Pharma Income Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 9,110 | 62.69 | 342.79 | 103.99 | 108.55 | 192 | Upgrade | |
Revenue Growth (YoY) | 2375.69% | -81.71% | 229.65% | -4.20% | -43.47% | 364.52% | Upgrade |
Cost of Revenue | -5.4 | 7.87 | 3.2 | - | 10.97 | - | Upgrade |
Gross Profit | 9,115 | 54.82 | 339.59 | 103.99 | 97.58 | 192 | Upgrade |
Selling, General & Admin | 461.11 | 404.02 | 215.93 | 269.51 | 298.21 | 222.39 | Upgrade |
Research & Development | 1,272 | 919.87 | 684.9 | 614.04 | 581.51 | 595.85 | Upgrade |
Other Operating Expenses | 196.42 | - | - | 48.27 | - | - | Upgrade |
Operating Expenses | 1,929 | 1,324 | 900.83 | 920.59 | 879.72 | 818.24 | Upgrade |
Operating Income | 7,186 | -1,269 | -561.24 | -816.6 | -782.14 | -626.24 | Upgrade |
Interest Expense | -280.28 | -34.05 | -25.83 | -57.79 | -4.09 | -49.31 | Upgrade |
Interest & Investment Income | 169.64 | 169.64 | 45.32 | 6.54 | 0.04 | 2.02 | Upgrade |
Currency Exchange Gain (Loss) | 18.29 | 18.29 | -9.71 | 25.6 | 36.52 | - | Upgrade |
Other Non Operating Income (Expenses) | 72.24 | -17.46 | -1.99 | 11.01 | -3.47 | - | Upgrade |
EBT Excluding Unusual Items | 7,166 | -1,133 | -553.44 | -831.24 | -753.14 | -673.53 | Upgrade |
Merger & Restructuring Charges | - | - | - | -19.1 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | 52.34 | 52.34 | -8.84 | 2.34 | -3.57 | - | Upgrade |
Asset Writedown | - | - | -11 | -1.46 | -2.17 | - | Upgrade |
Legal Settlements | -3.14 | -3.14 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | -135.59 | -122.58 | - | - | Upgrade |
Pretax Income | 7,215 | -1,083 | -708.87 | -972.04 | -758.89 | -673.53 | Upgrade |
Income Tax Expense | 534 | -4.62 | -5.13 | -6.43 | -3.95 | -4.81 | Upgrade |
Earnings From Continuing Operations | 6,681 | -1,079 | -703.74 | -965.61 | -754.94 | -668.71 | Upgrade |
Earnings From Discontinued Operations | - | - | - | -236.53 | -263.21 | -178.02 | Upgrade |
Net Income | 6,681 | -1,079 | -703.74 | -1,202 | -1,018 | -846.73 | Upgrade |
Net Income to Common | 6,681 | -1,079 | -703.74 | -1,202 | -1,018 | -846.73 | Upgrade |
Shares Outstanding (Basic) | 71 | 66 | 57 | 46 | 43 | 38 | Upgrade |
Shares Outstanding (Diluted) | 71 | 66 | 57 | 46 | 43 | 38 | Upgrade |
Shares Change (YoY) | 18.37% | 17.40% | 22.49% | 7.77% | 11.73% | 13.51% | Upgrade |
EPS (Basic) | 94.49 | -16.24 | -12.44 | -26.02 | -23.75 | -22.07 | Upgrade |
EPS (Diluted) | 93.68 | -16.24 | -12.44 | -26.02 | -23.75 | -22.07 | Upgrade |
Free Cash Flow | 7,528 | -940.87 | -436.91 | -954.02 | -1,234 | -713.76 | Upgrade |
Free Cash Flow Per Share | 105.56 | -14.16 | -7.72 | -20.65 | -28.79 | -18.60 | Upgrade |
Gross Margin | 100.06% | 87.44% | 99.07% | 100.00% | 89.89% | 100.00% | Upgrade |
Operating Margin | 78.88% | -2024.33% | -163.73% | -785.30% | -720.57% | -326.16% | Upgrade |
Profit Margin | 73.34% | -1720.87% | -205.30% | -1156.05% | -937.99% | -441.00% | Upgrade |
Free Cash Flow Margin | 82.64% | -1500.80% | -127.46% | -917.45% | -1136.94% | -371.75% | Upgrade |
EBITDA | 7,195 | -1,258 | -554.7 | -729.52 | -768.57 | -583.54 | Upgrade |
EBITDA Margin | 78.98% | - | -161.82% | - | - | - | Upgrade |
D&A For EBITDA | 9.12 | 10.58 | 6.54 | 87.08 | 13.57 | 42.69 | Upgrade |
EBIT | 7,186 | -1,269 | -561.24 | -816.6 | -782.14 | -626.24 | Upgrade |
EBIT Margin | 78.88% | - | -163.73% | - | - | - | Upgrade |
Effective Tax Rate | 7.40% | - | - | - | - | - | Upgrade |
Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.